Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.47 |
| ▸ | GABRP | O00591 | 3/20 | 0.47 |
| ▸ | GABRD | O14764 | 3/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.47 |
| ▸ | GABRE | P78334 | 3/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624625 | 0.84 | ADRA2A (0.46) | GABRA5GABRB2GABRPGABRDGABRA1 | |
| SCHEMBL30728065 | 0.82 | ADRA2A (0.40) | GABRA5GABRB2GABRPGABRDGABRA1 | |
| SCHEMBL7996551 | 0.81 | FFAR1 (0.55) | GABRA5GABRB2GABRPGABRDGABRA1 | |
| SCHEMBL4178273 | 0.79 | CA2 (0.50) | GABRA5GABRB2GABRPGABRDGABRA1 | |
| SCHEMBL31028364 | 0.78 | MBOAT4 (0.42) | HSD17B10ADRA2AADRA2BADRA2CHPGD | |
| SCHEMBL9655945 | 0.78 | FFAR1 (0.45) | HSD17B10P4HTMCYP2C19CYP1A2FFAR1 | |
| SCHEMBL9267515 | 0.78 | MBOAT4 (0.42) | HSD17B10ADRA2AADRA2BADRA2CHPGD | |
| SCHEMBL18041383 | 0.77 | FTO (0.42) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9657521 | 0.77 | FFAR1 (0.44) | FFAR1MAPT | |
| SCHEMBL1505803 | 0.77 | ALDH1A1 (0.45) | ADRA2AADRA2BADRA2CCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2790511-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| CN-105073738-A | Quinoline and quinazoline amides as modulators of sodium channels | VERTEX PHARMA | 2015-11-18 | — | — | CN | disclosed |
| CN-104968647-A | Amides as modulators of sodium channels | VERTEX PHARMA | 2015-10-07 | — | — | CN | disclosed |
| CN-104718206-A | Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides | BAYER CROPSCIENCE AG | 2015-06-17 | — | — | CN | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| CN-101967146-B | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC | 2015-04-08 | — | — | CN | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1995033724-A1 | PHENETHANOLAMINE DERIVATIVES AND THEIR USE AS ATYPICAL BETA-ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | GABRA5 2965/4885GABRB2 3140/4885GABRP 3199/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | GABRA5 590/4885GABRB2 677/4885GABRP 755/4885 |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | GABRA5 1371/4885GABRB2 1230/4885GABRP 1806/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | GABRA5 1420/4885GABRB2 2096/4885GABRP 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.